ZymoGenetics (ZGEN) Announces Promising Preliminary Results from Phase 2 Study of IL-21
Tweet Send to a Friend
ZymoGenetics, Inc. (NASDAQ: ZGEN) today announced that Interleukin 21 (IL-21) demonstrated an impressive overall response rate in the treatment of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
